Vistim Labs provides Ceregram, an in‑office, radiation‑free system that uses patented Evoked Potential Tomography to map sensory‑deficit patterns and quantify amyloid, tau, neurodegeneration, and cognitive performance. The device delivers objective, longitudinal measurements of disease progression and therapy response, enabling neurologists and memory‑clinic physicians to adjust treatment plans quickly and improve patient outcomes.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AIFounders
Product
Problem
Clinicians lack a quick, radiation‑free method to assess whether therapies for dementia and other neurodegenerative diseases are having a measurable effect, forcing reliance on infrequent imaging or subjective cognitive tests.
Solution
Vistim Labs offers Ceregram, a point‑of‑care system that uses patented Evoked Potential Tomography (EPT) to map sensory‑deficit patterns in the brain. By delivering precise, quantitative measurements of amyloid and tau accumulation, neurodegeneration, and cognitive performance, the device enables physicians to track disease progression and therapeutic response during routine visits. The technology provides objective, longitudinal data without radiation, allowing clinicians to adjust treatment plans promptly and improve patient outcomes.
Target Audience
Primary customers are neurologists, geriatric physicians, and memory‑clinic specialists who need objective, repeatable measures of therapy efficacy in patients with Alzheimer’s, Parkinson’s, Lewy body disease, and related disorders.
Features
- Patented Evoked Potential Tomography (EPT) that localizes and quantifies sensory deficits linked to neurodegenerative pathology
- Simultaneous assessment of multiple disease hallmarks: amyloid/tau burden, neurodegeneration, and cognitive test scores
- In‑office, radiation‑free testing workflow suitable for routine clinical use
- Automated data analysis and reporting that visualizes changes over time for individual patients
- Compatibility with standard neurological assessments (e.g., MMSE, CERAD, TASIT) for integrated reporting